News | Breast Imaging | November 08, 2018

Advanced Imaging Tool for Breast Cancer Surgery

The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.

KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen Tomosynthesis System will be on display at the Radiological Society of North America (RSNA) in Chicago, IL, Nov. 25-29, 2018.

Built on KUBTECs proprietary specimen tomosynthesis technology, The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery. The Mozart Supra System provides surgeons, radiologists and pathologists with the most advanced tools to provide the best quality of care for breast cancer patients.

Tomosynthesis has proven to be more effective than traditional 2-Dimensional imaging at identifying cancer in mammography and is now available for specimen imaging in the operating room and pathology lab.  This 3-D imaging technology enables surgeons to reduce the need for repeat surgeries and assists them in achieving more pleasing cosmetic outcomes for their patients.

John Leach, vice president of marketing at KUBTEC, said, “With the introduction of the Mozart Supra System, breast surgeons and pathologists can now view 3-Dimensional images of specimens of all sizes, from lymph nodes to mastectomies, solid organs and bone.  What’s more, the system uses an advanced Augmented Intelligence to aid the physician with image interpretation and includes voice activation for hands free usage in the OR.”

The MOZART Supra and MOZART Systems from KUBTEC are the onlyintraoperative breast specimen imaging systems to use tomosynthesis. Other features of the MOZART Supra include: auto-magnification, KUBTEC’s patented Image Blender and a high definition optical camera.

More details on the KUBTEC Mozart Supra Specimen Tomosynthesis System can be found at: www.kubtec.com/supra


Related Content

News | Women's Health

March 4, 2026 — QT Imaging Holdings recently announced that Mary W. Yamashita, MD will serve as medical advisor to the ...

Time March 06, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Women's Health

Feb.23, 2026 — The first clinical patient received a Clairity Breast cancer risk score, marking a historic milestone in ...

Time February 23, 2026
arrow
News | Breast Biopsy Systems

Feb. 18, 2026 — Mammotome, a Danaher company, has introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy ...

Time February 18, 2026
arrow
News | Breast Imaging

Feb. 16, 2026 — Rising demand for breast cancer screening and diagnostics is outpacing the supply of available breast ...

Time February 17, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
Subscribe Now